Market Place
Sourcing Support
All News #Library
Biotech
Amolyt Abstracts Accepted At GRS Congress, ECE And ENDO Conferences
07 May 2024 //
GLOBENEWSWIRE
Amolyt`s Eneboparatide Gets FDA Fast Track For Hypoparathyroidism
02 May 2024 //
GLOBENEWSWIRE
Amolyt Named ˜Biotech Company of the Year™ at the LSX European Lifestars Awards
16 Nov 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Two Poster Presentations at ASBMR
03 Oct 2023 //
GLOBENEWSWIRE
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide
27 Sep 2023 //
GLOBENEWSWIRE
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide
07 Jun 2023 //
GLOBENEWSWIRE
Amolyt Announces Initiation of Phase 1 Clinical Trial of Peptide GHRA, AZP-3813
05 Jun 2023 //
GLOBENEWSWIRE
Amolyt Pharma Launches Public Awareness Campaign
01 Jun 2023 //
GLOBENEWSWIRE
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
05 May 2023 //
PHARRMIWEB
Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide
02 May 2023 //
GLOBENEWSWIRE
Amolyt hauls in €130M round to fund PhIII trial of hypoparathyroidism drug
06 Jan 2023 //
ENDPTS
Amolyt Pharma Announces $138 M Series C Financing led by Sofinnova Partners
06 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.